After participating in 26 "national negotiations," AstraZeneca's "top negotiator" has left.

After Huang Bin’s departure, how will AstraZeneca’s national negotiation strategy evolve?

On March 18, AstraZeneca China suddenly announced that Huang Bin, the company’s Vice President in China and head of the Market Access Department, has officially left. This marks another major leadership change in China following the departure of former China President Lei Wang.

As a veteran of AstraZeneca China, Huang Bin previously served as the legal representative of AstraZeneca Investment (China) Co., Ltd., AstraZeneca Pharmaceuticals (Shanghai) Co., Ltd., and AstraZeneca Pharmaceuticals (China) Co., Ltd. He stepped down from these legal representative roles successively in May 2024, May 2025, and June 2025.

Meanwhile, Huang Bin also serves as an independent director at Yaihong Pharmaceutical, a domestic biopharmaceutical company. He has not yet responded to First Financial News regarding his future plans after leaving.

Huang Bin is a core figure in AstraZeneca’s Market Access Department, having led teams in numerous national medical insurance negotiations. He has participated in 26 negotiations, helping to include multiple innovative drugs such as Durvalumab and Capecitabine into the medical insurance catalog, and has extensive experience in drug pricing in China. He has also become one of the most closely watched corporate negotiators in national negotiations, earning the nickname “Gold Medal Negotiator” after humorously commenting on reporters’ expressions post-negotiation.

In recent years, multinational pharmaceutical companies have faced increasing challenges in national negotiations, including making concessions on prices even for newly launched innovative drugs. In an interview, Huang Bin discussed how to ensure the motivation of original research-based pharmaceutical companies, stating: “I believe that good innovative drugs will ultimately face imitation and collective procurement, but we should also consider protecting and encouraging the early R&D investments of innovative original research companies under certain circumstances.”

Huang Bin has also actively called for extending patent protection periods for innovative drugs. Previously, AstraZeneca’s partner Fabbio’s original drug Rosuvastatin faced a harsh price war after its patent expired.

Huang Bin’s departure is another intense ripple in AstraZeneca China’s leadership reshuffle. Since Lei Wang left the position of President of AstraZeneca China in 2024, the second half of 2025 has seen a period of intensive restructuring, including the establishment of a Gastrointestinal Tumor Business Unit and an Early Business Pipeline Department; the biopharmaceutical sector has been optimized into two major divisions: respiratory biologics and autoimmune, and respiratory inhalation. The “Corporate Affairs and Market Access Department” where Huang Bin worked has also been split into an independent department.

The frequent organizational adjustments in AstraZeneca China reflect strategic optimization, as the company actively focuses on next-generation innovative drugs, especially in cutting-edge fields like cell therapy.

Following AstraZeneca’s announcement last month of a plan to invest over 100 billion RMB in China by 2030, on March 19, AstraZeneca announced plans to establish a cell therapy commercialization and production base and an innovation center in the Shanghai Lingang New Area. This facility will be used for commercial production and supply of autologous CAR-T cell therapies in China and other Asian markets, including a bispecific CAR-T cell therapy developed on the Gengxi Bio platform, currently in clinical trials for multiple myeloma and autoimmune diseases. The company will also establish the AstraZeneca Gengxi Cell Therapy Innovation Center in Zhangjiang High-Tech Park, covering early research, viral vector and plasmid development, analytical testing, clinical production, and registration support.

(Article from First Financial News)